OrthoPediatrics Corp. Common Stock
KIDSUnited States
5 filed reports · 250 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 705 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 764 | Dec 2025 |
Financial data
250 concepts · 1,469 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial247 concepts · 1,405 facts · Dec 2023 to Jun 2026
- Stockholders equity (US GAAP)14 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents13 · Dec 2023 to Jun 2026
- Net income loss13 · Dec 2023 to Jun 2026
- Other comprehensive income loss net of tax portion attributable to parent13 · Dec 2023 to Jun 2026
- Stock issued during period value restricted stock award net of forfeitures13 · Dec 2023 to Jun 2026
- Comprehensive income net of tax12 · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)12 · Dec 2023 to Jun 2026
- General and administrative expense (US GAAP)12 · Dec 2023 to Jun 2026
- Gross profit (US GAAP)12 · Dec 2023 to Jun 2026
- Income tax expense benefit12 · Dec 2023 to Jun 2026
- Interest expense debt12 · Dec 2023 to Jun 2026
- Interest expense nonoperating12 · Dec 2023 to Jun 2026
- Nonoperating income expense12 · Dec 2023 to Jun 2026
- Operating expenses (US GAAP)12 · Dec 2023 to Jun 2026
- Operating income loss12 · Dec 2023 to Jun 2026
- Other comprehensive income availableforsale securities adjustment net of tax portion attributable to parent12 · Dec 2023 to Jun 2026
- Other comprehensive income foreign currency transaction and translation adjustment net of tax portion attributable to parent12 · Dec 2023 to Jun 2026
- Other comprehensive income loss available for sale securities adjustment before reclassification adjustments net of tax12 · Dec 2023 to Jun 2026
- Other nonoperating income expense12 · Dec 2023 to Jun 2026
- Research and development expense12 · Dec 2023 to Jun 2026
- Revenue12 · Dec 2023 to Jun 2026
- Selling and marketing expense (US GAAP)12 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect11 · Dec 2023 to Jun 2026
- Deferred income tax expense benefit11 · Dec 2023 to Jun 2026
Product2 concepts · 40 facts · Dec 2023 to Jun 2026
- Revenue34 · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)6 · Dec 2023 to Dec 2025
Geography1 concepts · 24 facts · Dec 2023 to Jun 2026
- Revenue24 · Dec 2023 to Jun 2026
Segments
64 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service6 members · 40 facts
- Spine12 · Dec 2023 to Jun 2026
- Sports Medicine And Other12 · Dec 2023 to Jun 2026
- Trauma And Deformity7 · Jun 2024 to Jun 2026
- Shipping And Handling Billed3 · Dec 2023 to Dec 2025
- Shipping And Handling Not Billed3 · Dec 2023 to Dec 2025
- Traumaand Deformity3 · Dec 2023 to Dec 2025
Statement geographical2 members · 24 facts
- Non Us12 · Dec 2023 to Jun 2026
- US12 · Dec 2023 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
4 calls · Oct 2025 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 4, 2026
- FY2026 Q1Apr 30, 2026
- FY2025 Q4Feb 26, 2026
- FY2025 Q3Oct 28, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.